Condition: Solid Tumor · Colorectal Cancer · Non-small Cell Lung Cancer · Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
This is a phase 1 multi-center, open-label study evaluating IBI3028 Treatment in participants with locally advanced, unresectable, or metastatic solid tumors
This description comes directly from the study's public registry record.
Shijie Liu · (+86)18701121959 · shijie.liu@innoventbio.com
Always discuss trial participation with your own doctor first.
| Tianjin Medical University Cancer Institute and Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07589205